Download PDF
Exp Clin Endocrinol Diabetes 2000; Vol. 108(3): 151-163
DOI: 10.1055/s-2000-7737
Review

© Johann Ambrosius Barth

Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus

Martin Füchtenbusch 1 , Eberhard Standl 1 , Helmut Schatz 2
  • 1 Diabetes Research Institute and 3rd Medical Department, Academic Hospital München-Schwabing, Munich, Germany
  • 2 Medical University Clinic Bergmannsheil, Ruhr-University, Bochum, Germany
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Also available at
    Permissions and Reprints

Summary:

A central finding of the UKPDS was that in type 2 diabetic patients, tight glycemic control with HbA1c targets as close to the normal range as possible must be achieved to further reduce diabetes related-complications, -mortality, and -cardiovascular disease, highlighting the need for new, optimized treatment strategies. With a focus on clinical efficacy, this paper discusses the results from the 20 major therapeutical trials published in the years 1997-1999, that evaluated the new insulinsensitizing thiazolidinediones Rosiglitazone and Pioglitazone and the new insulin-releasing potassium channel blockers Repaglinide and Nateglinide. While for Nateglinide, promising, but only preliminary data is available at current, Rosiglitazone, Pioglitazone, and Repaglinide have been shown appropriate for both mono- and combination therapy with current standard drug treatment of type 2 diabetes. Similar to the known, older antidiabetic drugs, the new agents discussed have comparable blood glucose lowering potentials with a dose-related capacity of 0.5 to 1.5% HbA1c reduction. These beneficial effects were both seen in drug-naive patients previously treated with diet only and in combination therapies where patients had previous antidiabetic standard drug treatment suggesting effectiveness of glitazones and glinides also in more advanced stages of the disease. Problems with adverse effects appeared minor although longe-range implications of weight gain, edema, lowering of hemoglobin, increase of total cholesterol for the glitazones, and hypoglycemia for glinides warrant further consideration. What becomes clear from the variety of most recent mono- and combination treatment studies with as much as five different classes of antidiabetic drugs is that individually tailored therapies that recognize quality of life parameters and target the predominant features of metabolic pathology (such as early postprandial versus fasting hyperglycemia, degree of insulin resistance, progressive loss of β-cell function) may become a feasible goal in the future.

Key words:

glinides - insulin sensitizer - insulin secretagogues - hypoglycemia - insulin resistance - prandial glucose regulation - glycaemic control - combination therapy - repaglinide - nateglinide - rosiglitazone - pioglitazone - responder - glitazones

References

  • 1 Beebe K L. Rosiglitazone is effective and well tolerated in patients ≥ 65 years with type 2 diabetes.  Diabetologia 42 ((Suppl 1) A227) 854 1999; 
    PubMedGoogle Scholar
  • 2 Bretzel R G, Voigt K, Schatz H. The United Kingdom Prospective Diabetes Study (UKPDS) Implications for the Pharmacotherapy of Type 2 Diabetes Mellitus.  Exp Clin Endocrinol Diabetes. 106 369-372 1998; 
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Chuang L M, Juang J H, Wu H P, Chiang Y D, Li K L, Jorgensen L N, Tai T Y. Clinical efficacy and safety of NovoNorm® in the treatment of Chinese Type 2 diabetes in Taiwan.  Diabetologia 42 ((Suppl 1) A241) 908 1999; 
    PubMedGoogle Scholar
  • 4 Cranmer H, Jones N P, Patwrdhan R. Rosiglitazone is effective in both obese and non-obese patients with type 2 diabetes.  Diabetologia 42 ((Suppl 1) A228) 856 1999; 
    CrossrefPubMedGoogle Scholar
  • 5 Damsbo P, Clauson P, Marbury T C, Windfeld K. A double-blind randomized comparison of meal-related glycemic control by Repaglinide and Glyburide in well-controlled type 2 diabetic patients.  Diabetes Care. 22 789-794 1999; 
    PubMedGoogle Scholar
  • 6 Dejgaard A, Madsbad S, Kilhovd B, Lager I, Mustajoki P. Repaglinide compared to Glipizide in the treatment of type 2 diabetic patients.  Diabetologia 41 ((Suppl 1) A236) 914 1998; 
    PubMedGoogle Scholar
  • 7 Egan J, Rubin C, Mathisen A. Pioglitazone 027 Study group . Combination therapy with Pioglitazone and Metformin in patients with Type 2 diabetes.  Diabetes 48 ((Suppl 1) A117) 0504 1999; 
    PubMedGoogle Scholar
  • 8 European NIDDM Policy group 1998-1999 . A desktop guide to type 2 diabetes mellitus.  Exp Clin Endocrinol Diabetes. 107 390-420 1999; 
    PubMedGoogle Scholar
  • 9 Fonseca V, Biswas N, Salzmann A. Rosiglitazone in combination with Metformin effectively reduces hyperglycemia in patients with Type 2 diabetes.  Diabetologia 42 ((Suppl 1) A230) 864 1999; 
    PubMedGoogle Scholar
  • 10 Frandsen K B, Moses R, Gomis R, Clauson P. Efficacy and safety study of Repaglinide, a flexible prandial glucose regulator, in type 2 diabetes patients.  Diabetologia 42 ((Suppl 1) A242) 910 1999; 
    PubMedGoogle Scholar
  • 11 Fuhlendorff J, Rorsman P, Kofod H, Brand C L, Rolin B, MacKay P, Shymko R, Carr R D. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes.  Diabetes. 47 345-351 1998; 
    CrossrefPubMedGoogle Scholar
  • 12 Glatt M, Schatz H. The influence of an acyl-amino-alcyl-benzoic acid (HB 699) on biosynthesis and secretion of insulin in isolated rat islets of Langerhans.  Diabe & Metabolisme (Paris). 7 105-108 1981; 
    PubMedGoogle Scholar
  • 13 Goldberg R B, Einhorn D, Lucas C P, Rendell M S, Damsbo P, Huang W-C, Strange P, Brodows R G. A randomized placebo-controlled trial of Repaglinide in the treatment of type 2 diabetes.  Diabetes Care. 21 1897-1998 1998; 
    CrossrefPubMedGoogle Scholar
  • 14 Goldstein B, Salzmann A. Rosiglitazone in poorly controlled type 2 diabetes patients.  Diabetologia 42 ((Suppl 1) A229) 861 1999; 
    PubMedGoogle Scholar
  • 15 Gomis R, Jones N P, Vallance S E, Patwardhan R. Low-dose Rosiglitazone enhances glycemic control when combined with sulphonylureas in Type 2 diabetes.  Diabetologia 42 ((Suppl 1) A227) 851 1999; 
    PubMedGoogle Scholar
  • 16 Grunberger G, Weston W M, Patwardhan R, Rappaport E B. Rosiglitazone once or twice daily improves glycemic control in patients with type 2 diabetes.  Diabetologia 42 ((Suppl 1) A4) 8 1999; 
    PubMedGoogle Scholar
  • 17 Hirschberg Y, McLeod J, Gareffa S, Spratt D. Pharmacodynamics and dose response of nateglinide in type 2 diabetics.  Diabetes 48 ((Suppl 1) A100) 0430 1999; 
    PubMedGoogle Scholar
  • 18 Jones N P, Charbonnel B, Lönnquist F, Owen S, Patwardhan R. Rosiglitazone reduces plasma insulin and ist precursors while decreasing glycemia in type 2 diabetes.  Diabetologia 42 ((Suppl 1) A229) 859 1999; 
    PubMedGoogle Scholar
  • 19 Kalbag J, Hirschberg Y, McLeod J, Gareffa S, Lasseter K. Comparison of mealtime glucose regulation by Nateglinide and Repaglinide in Healthy subjects.  Diabetes 48 ((Suppl 1) A167) 0456 1999; 
    PubMedGoogle Scholar
  • 20 Kreider M, Miller E, Patel J. Rosiglitazone (RSG) is safe and well tolerized as montherapy or combination therapy in patietns with type 2 diabetes mellitus.  Diabetes 48 ((Suppl 1) A117) 0506 1999; 
    PubMedGoogle Scholar
  • 21 Landin-Olsson M, Brogard M, Erikkson J, Rasmussen M, Clauson P. The efficacy of Repaglinide administered in Combination with bestime NPH-insulin in patients with type 2 diabetes. A randomized, semi-blinded, parallel Group, Multicenter Trial.  Diabetes 48 ((Suppl 1) A117) 0503 1999; 
    PubMedGoogle Scholar
  • 22 Lebovitz H E, Patel J, Dole J, Patwardhan R. Rosiglitazone (BRL 49653) Monotherapy has significant Glucose effect in type 2 diabetic patients.  Diabetologia 41 ((Suppl 1) A238) 922 1998; 
    PubMedGoogle Scholar
  • 23 Lönnqvist F, Charbonnel B, Jones N P, Abel M G, Patwardhan R. Rosiglitazone is superior to Glibenclamide in reducing fasting plasma glucose in Type 2 diabetic patients.  Diabetologia 42 ((Suppl 1) A231) 869 1999; 
    PubMedGoogle Scholar
  • 24 Mathisen A, Geerlof J, Houser V. on behalf of the Pioglitazone 026 Study group . The effect of Pioglitazone on glucose control and lipid profile in patients with type 2 diabetes.  Diabetologia 8 ((Suppl 1) A227) 853 1999; 
    PubMedGoogle Scholar
  • 25 Matthews D R, Bakst A, Weston W M, Hemyari P. Rosiglitazone decreases insulin resistance and improves beta-cell function in patients with type 2 diabetes.  Diabetologia 42 ((Suppl 1) A228) 858 1999; 
    PubMedGoogle Scholar
  • 26 Matthews D R, Hosker J P, Rudensky A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 28 312-419 1985; 
    PubMedGoogle Scholar
  • 27 Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, Donelly T, Moffitt P, Hopkins H. Effect of Repaglinide addition to Metformin monotherapy on glycemic control in patients with Type 2 Diabetes.  Diabetes Care. 22 119-124 1999; 
    CrossrefPubMedGoogle Scholar
  • 28 Nathan D M. Some answers, more controversy, from UKPDS.  Lancet. 352 832-833 1998; 
    PubMedGoogle Scholar
  • 29 Nolan J J, Jones N P, Patwardhan R, Deacon L F. Once-daily Rosiglitazone is effective in the treatment of type 2 diabetes mellitus.  Diabetes 48 ((Suppl 1) A111) 0478 1999; 
    PubMedGoogle Scholar
  • 30 Patel J, Anderson R J, Rappaport E B. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomised, placebo-controlled study.  Diabetes, Obesity and Metabolism. 1 165-172 1999; 
    CrossrefPubMedGoogle Scholar
  • 31 Polonsky K S, Given B D, Hirsch L, Shapiro E T, Tillil H, Beebe C, Galloway J A, Frank B H, Karrison T, Van Gouter E. Quantitative study of insulin secretion and clearance in normal and obese subjects.  J Clin Invest. 81 435-441 1988; 
    PubMedGoogle Scholar
  • 32 Polonsky K S, Given B D, Hirsch L J, Tillil H, Shapiro E T, Beebe C, Frank B H, Galloway J A, Van Gouter E. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus.  N Engl J Med. 318 1231-1239 1988; 
    CrossrefPubMedGoogle Scholar
  • 33 Polonsky K S. Evolution of β-cell dysfunction in impaired glucose tolerance.  Exp Clin Endocrinol Diabetes 107 ((Suppl 4)) 124-127 1999; 
    PubMedGoogle Scholar
  • 34 Raskin P, Dole J F, Rappaport E B. Rosiglitazone (RSG) improves glycemic control in poorly controlled, insulin-treated Type 2 Diabetes (T2D).  Diabetes 48 ((Suppl 1) A94) 0404 1999; 
    PubMedGoogle Scholar
  • 35 Raskin P, Kennedy F, Woo V, Rajeev J, Boss A H. A multicenter, randomized study of the therapeutic effect of Repaglinide combined with troglitazone in subjects with type 2 diabetes.  Diabetes 48 ((Suppl 1) A107) 0463 1999; 
    PubMedGoogle Scholar
  • 36 Rubin C, Egan J, Schneider R. Pioglitazone 014 Study group . Combination therapy with Pioglitazone and Insulin in Patients with Type 2 Diabetes.  Diabetes 48 ((Suppl 1) A110) 0474 1999; 
    PubMedGoogle Scholar
  • 37 Salzman A. Rosiglitazone is not associated with hepatotoxicity.  Diabetologia 42 ((Suppl 1) A3) 2 1999; 
    PubMedGoogle Scholar
  • 38 Schatz H. Preclinical and clinical studies on safety and tolerability of repaglinide.  Exp Clin Endocrinol Diabetes 107 ((Suppl 4)) S144-S148 1999; 
    PubMedGoogle Scholar
  • 39 Schneider R, Egan J, Houser V. Pioglitazone 010 Study Group . Combination therapy with Pioglitazone and Sulphonylurea in Patients with Type 2 diabetes.  Diabetes 48 ((Suppl 1) A106) 0458 1999; 
    PubMedGoogle Scholar
  • 40 Schneider R, Lessem J, Lekich R. Pioglitazone is efeective in the treatment of patients with Type 2 diabetes.  Diabetes 48 ((Suppl 1) A109) 0469 1999; 
    PubMedGoogle Scholar
  • 41 Singer D E, Nathan D M, Anderson K M, Wilson P WF, Evans J C. Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study.  Diabetes. 41 202-208 1992; 
    PubMedGoogle Scholar
  • 42 Spiegelman B M. PPAR-γ: Adipogenic regulator and thiazolidinedion receptor.  Diabetes. 47 (4) 507-514 1998; 
    CrossrefPubMedGoogle Scholar
  • 43 Tabona M V, Weill S, Patwardhan R. Rosiglitazone given once or twice daily is effective first-line treatment for type 2 Diabetes mellitus.  Diabetologia 42 ((Suppl 1) A231) 867 1999; 
    PubMedGoogle Scholar
  • 44 UKPDS Group . Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).  Lancet. 352 854-865 1998; 
    CrossrefPubMedGoogle Scholar
  • 45 UKPDS Group . Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 352 837-853 1998; 
    CrossrefPubMedGoogle Scholar
  • 46 Uusitupa M IJ, Niskanen L K. Hyperglycemia and cardiovascular risk in NIDDM.  Diabetes Care. 18 884-885 1995; 
    PubMedGoogle Scholar
  • 47 Watkins P B, Whitcomb R W. Hepatic dysfunction associated with troglitazone.  N Engl J Med. 338 916-917 1998; 
    CrossrefPubMedGoogle Scholar
  • 48 Whitcomb R W, Saltiel A R. Thiazolidinediones.  Expert Opin Invest Drug. 4 (12) 1299-1309 1995; 
    PubMedGoogle Scholar
  • 49 Wolffenbuttel B HR, Landgraf R. on behalf of the Dutch and German Repaglinide Study group . A 1-year multicenter randomized double-blind comparison of repaglinide and Glyburide fir the treatment of Type 2 diabetes.  Diabetes Care. 22 463-468 1999; 
    CrossrefPubMedGoogle Scholar
  • 50 Zimmet P Z. Diabetes epidemiology as a tool to trigger diabetes research and care.  Diabetologia. 42 499-518 1999; 
    CrossrefPubMedGoogle Scholar

1 *** p < 0.0001, ** p< 0.0003, * p < 0.05, 1) p = 0.05, n.r.: not reported, SD are not given in this table for better readability._FPG: fasting plasma glucose

2 *** p < 0.0001, * p < 0.05, n.r.: not reported, SD are not given in this table for better readability. 1) (SU permitted were glibenclamide, glipizide, and gliclazid), 2) (metformin at a maximal dose of 2.5 g/day in inadequately controlled diabetes), 3) (poorly controlled diabetes with metformin of any dose prior to enrolment), 4) (enrolment of patients with insulin dose of >30 Units/day)._FPG: fasting plasma glucose

3 *** p < 0.0001, ** p < 0.001, * p < 0.01, n.r.: not reported, SD are not given in this table for better readability. 1) (titration period of 4 weeks by `one-meal, one tablet' principle, thereafter doses were increased to 1 mg/meal if FBG > 7.8 mmol), 2) (until week 8, doses were titrated according to FPG goals of 5-9 mmol/l. 36% of patients thereafter were treated with 4 mg and 76% with 8 mg Repaglinide), 3) (6-8 week dose titration from 0.5-4 mg), 4) (FPG only reported from home blood glucose measurements)._FPG: fasting plasma glucose

4 *** p < 0.001, ** p < 0.01 between treatment groups, * p < 0.05, a) p < 0.05 for comparison Trogl. + Repa. vs. Trogl. vs. Repa., and Repa. vs. Trogl. n.r.: not reported, PBO: placebo, SD are not given in this table for better readability. 1) (titration period of 4-8 weeks with `one-meal, one tablet' principle, thereafter doses were stepwise increased to 4 mg/meal if FPG > 7.8 mmol), 2) (27 patients of the 83 included withdrew during randomizazion), 3) (forced titration from week 0 to week 4, fixed dose until week 14, thereafter titration to maximum dose)._FPG: fasting plasma glucose

Prof. Dr. Eberhard Standl

Diabetes Research Institute and 3rd Medical Department,

Academic Hospital München-Schwabing

Kölner Platz 1,

D-80804 Munich,

Germany

Fax: +49 89 30 68 3906

Email: Eberhard.Standl@lrz.uni-muenchen.de

      >